154 related articles for article (PubMed ID: 25100024)
1. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
Luo F; Gu J; Chen L; Xu X
Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024
[TBL] [Abstract][Full Text] [Related]
2. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Ryu S; Imai YN; Oiki S
Bioorg Med Chem Lett; 2013 Jul; 23(13):3848-51. PubMed ID: 23711922
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
4. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs.
Negami T; Araki M; Okuno Y; Terada T
Sci Rep; 2019 Nov; 9(1):16586. PubMed ID: 31719645
[TBL] [Abstract][Full Text] [Related]
5. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
6. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Alexandrou AJ; Duncan RS; Sullivan A; Hancox JC; Leishman DJ; Witchel HJ; Leaney JL
Br J Pharmacol; 2006 Apr; 147(8):905-16. PubMed ID: 16474415
[TBL] [Abstract][Full Text] [Related]
8. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
Masetti M; Cavalli A; Recanatini M
J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
[TBL] [Abstract][Full Text] [Related]
9. An automated docking protocol for hERG channel blockers.
Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
[TBL] [Abstract][Full Text] [Related]
10. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
11. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H
J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in computational prediction of HERG blockage.
Wang S; Li Y; Xu L; Li D; Hou T
Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
[TBL] [Abstract][Full Text] [Related]
13. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels.
Zünkler BJ; Claassen S; Wos-Maganga M; Rustenbeck I; Holzgrabe U
Toxicology; 2006 Dec; 228(2-3):239-48. PubMed ID: 17027138
[TBL] [Abstract][Full Text] [Related]
14. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
Hancox JC; James AF
Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
[TBL] [Abstract][Full Text] [Related]
15. A novel hypothesis for the binding mode of HERG channel blockers.
Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
[TBL] [Abstract][Full Text] [Related]
16. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
17. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
18. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
19. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods.
Osterberg F; Aqvist J
FEBS Lett; 2005 May; 579(13):2939-44. PubMed ID: 15893317
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine Attenuates hERG Channel by Promoting the Membrane Channel Degradation: Computational Simulation and Experimental Evidence for QT-Interval Prolongation with Hydroxychloroquine Treatment.
Wang X; Feng Y; Liu S; Liu J; Pan S; Wei L; Ma Y; Liu Z; Xing Y; Wang J; Cui Q; Zhang Y; Wang T; Cai C
Cardiology; 2023; 148(4):310-323. PubMed ID: 37231805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
